Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K2 | P36507 | 5/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.44 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29371646 | 1.00 | MAP2K2 (0.47) | MAP2K2MAP2K1CHRNA7KCNH2CHRNA1 | |
| Hydrochloric Acid SCHEMBL6206110 | 0.94 | CHRNA7 (0.48) | MAP2K2MAP2K1CHRNA7KCNH2CHRNA1 | |
| SCHEMBL6207836 | 0.92 | CHRNA7 (0.46) | MAP2K2MAP2K1CHRNA7KCNH2CHRNA1 | |
| SCHEMBL6205441 | 0.92 | CHRNA7 (0.46) | MAP2K2MAP2K1CHRNA7KCNH2CHRNA1 | |
| SCHEMBL15598681 | 0.90 | CHRNA7 (0.44) | CHRNA7KCNH2CHRNA1CYP1A2CYP3A4 | |
| SCHEMBL6399220 | 0.88 | CHRNA7 (0.43) | CHRNA7KCNH2CHRNA1CYP1A2CYP3A4 | |
| SCHEMBL6206530 | 0.87 | CHRNA7 (0.43) | MAP2K2MAP2K1CHRNA7KCNH2CHRNA1 | |
| SCHEMBL6207282 | 0.87 | MAP3K8 (0.46) | MAP2K1CHRNA7KCNH2CHRNA1CYP1A2 | |
| SCHEMBL6399647 | 0.87 | CHRNA7 (0.48) | MAP2K2MAP2K1CHRNA7KCNH2CHRNA1 | |
| SCHEMBL6189562 | 0.86 | CHRNA7 (0.44) | MAP2K2MAP2K1CHRNA7KCNH2CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | claimed |
| US-20030224500-A1 | Modified MEK1 and MEK2, crystal of a peptide: ligand: cofactor complex containing such modified MEK1 or MEK2, and methods of use thereof | OHREN JEFFREY F (US) | 2003-12-04 | — | — | US | claimed |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250179077-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250163064-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250122222-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250059179-A1 | Heterocyclic Compounds and Methods of Use | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-20250059205-A1 | Heterocyclic Compounds and Methods of Use | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-20130059851-A1 | Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059851-A1 | Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011112678-A1 | METHODS OF DIAGNOSING AND TREATING CANCER IN PATIENTS HAVING OR DEVELOPING RESISTANCE TO A FIRST CANCER THERAPY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| EP-1578736-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| WO-2004056789-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20030224500-A1 | Modified MEK1 and MEK2, crystal of a peptide: ligand: cofactor complex containing such modified MEK1 or MEK2, and methods of use thereof | OHREN JEFFREY F (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003054180-A1 | MODIFIED MEK1 AND MEK2, CRYSTAL OF A PEPTIDE: LIGAND: COFACTOR COMPLEX CONTAINING SUCH MODIFIED MEK1 OR MEK2, AND METHODS OF USE THEREOF | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-03 | — | — | WO | disclosed |
| EP-1321518-A1 | Modified MEK1 and MEK2, crystal of a peptide: ligand: cofactor complex containing such modified MEK1 or MEK2, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2003-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179077-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | KRAS, NRAS, HRAS | MAP2K2 824/4885MAP2K1 1012/4885CHRNA7 4757/4885 |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | MAP2K2 615/4885MAP2K1 388/4885CHRNA7 4184/4885 |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | MAP2K2 1351/4885MAP2K1 1078/4885CHRNA7 4863/4885 |
| US-20250163064-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | KRAS, NRAS, HRAS | MAP2K2 768/4885MAP2K1 955/4885CHRNA7 4739/4885 |
| US-20250059179-A1 | Heterocyclic Compounds and Methods of Use | KRAS, NRAS, HRAS | MAP2K2 1574/4885MAP2K1 1728/4885CHRNA7 4840/4885 |
| US-20250059205-A1 | Heterocyclic Compounds and Methods of Use | KRAS, NRAS, HRAS | MAP2K2 1574/4885MAP2K1 1728/4885CHRNA7 4840/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | MAP2K2 138/4885MAP2K1 32/4885CHRNA7 4862/4885 |
| US-20050004186-A1 | MEK inhibiting compounds | MAPK1, MAP3K1, MAPK3 | MAP2K2 40/4885MAP2K1 46/4885CHRNA7 4667/4885 |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | MAP2K2 1351/4885MAP2K1 1078/4885CHRNA7 4863/4885 |
| US-20130059851-A1 | Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy | CRKL, RAF1, TPX2 | MAP2K2 41/4885MAP2K1 53/4885CHRNA7 4664/4885 |
| US-20250122222-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | MAP2K2 1028/4885MAP2K1 1160/4885CHRNA7 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.